【摘要】 目的　探讨组织蛋白酶D(Cathepsin ,CD)和P选择素 (Pseleltin ,Ps)在非小细胞肺癌 (NSCLC)中的表达及其临床意义。方法　应用免疫组织化学技术 (SP法 )检测 3 0例NSCLC石蜡切片组织中CD和Ps的表达。结果　CD和Ps的阳性率分别为 66 7%( 2 0 / 3 0 )、76 7%( 2 3 / 3 0 )。CD表达与肿块大小、病理分期及淋巴结转移呈正相关 (P <0 0 5 ) ,与 3年存活率呈负相关 (P <0 0 5 ) ,与患者年龄、性别、分化程度、病理类型无显著相关 (P >0 0 5 )。Ps表达则与患者年龄、性别、分化程度、肿块大小、病理类型、病理分期及 3年存活率均无关 (P >0 0 5 )。二者均阳性的患者 3年存活率为 2 5 0 %( 4 / 16) ,明显低于同时阴性者的 10 0 %( 3 / 3 ) (P <0 0 5 )。结论　CD可作为NSCLC淋巴结转移的重要标志 ,是高危预后指标。CD和Ps联合检测 ,可更精确地判断预后 ,为制定治疗方案提供依据更多还原

【Abstract】 Objective To investigate the correlation of Cathepsin D and P selectin expression with the clinico-pathologic features and prognosis of non-small cell lung cancer (NSCLC). Methods Immunohistochemistry (S-P method) was applied to detect the expression of Cathepsin D and P selection in 30 NSCLC specimens. Results The positive rates of cathepsin D and P selectin were 66 7% and 76 7% respectively. Cathepsin D expression in NSCLC was positive relation with the tumor size, TNM stage and lymph node metastasis(P<0 05), was negative relation with 3 years survival rate of the patients(P<0 05), and did not correlate with the patients’ age and gender, and the tumor pathological type and differentiated degree. P selectin expression in tumor vessles was not associated with the patients’ age and gender, tumor differentiated degree, tumor size, pathologic type and 3 years survival rate of the patient (P>0 05). The 3 years survival rate of the patients with the expression of both the Cathepsin D and P selectin was much lower than that of the patients with negative expression of both the Cathepsin D and P selectin(P<0 05). Conclusion The expression of Cathepsin D can be used to evaluate the lymph node metastasis and prognosis of NSCLC. Combination measurement of Cathepsin D and P selectin may be more significant for the prognosis evaluation, and helpful to provide a guide for reasonable treatment of NSCLC patients.更多还原